SEC Form 4 · accession 0001209191-15-047656
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gerald E Quirk
Officer — General Counsel, Executive VP
Period of report
May 26, 2015
Accepted (ET)
May 28, 2015 · 6:10 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.81 | May 26, 2015 | A | 214,605 | A | — | May 25, 2025 | Common Stock | 214,605 | 214,605 | D |
Explanation of responses
- F1This option vests with respect to 12.5% of the shares underlying the option vesting on November 26, 2015 and an additional 2.0833% monthly thereafter through May 26, 2019.